Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: A short-term model for evaluation of antiresorptive therapy

被引:17
作者
Stroup, GB
Hoffman, SJ
Vasko-Moser, JA
Lechowska, BA
Jenkins, EL
Dare, LC
Gowen, M
机构
[1] SmithKline Beecham Pharmaceut, Dept Bone & Cartilage Biol, King Of Prussia, PA 19406 USA
[2] SmithKline Beecham Pharmaceut, Dept Lab Anim Sci, King Of Prussia, PA 19406 USA
关键词
monkey; primate; gonadotropin-releasing hormone (GnRH) estrogen; bone turnover; antiresorptive;
D O I
10.1016/S8756-3282(01)00421-5
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
In this study we determine the early time course of estrogen deficiency-induced bone loss in the cynomolgus monkey and examine the potential of this method for evaluating antiresorptive therapies. In two groups of animals, estrogen deficiency was induced by the administration of a gonadotropin-releasing hormone agonist (GnRHa) and bone turnover was measured using biochemical markers, Two weeks after receiving GnRHa, serum estradiol decreased to below the detection limit in most animals and remained there through 6 months or until estrogen replacement started (months 4-6), Relative to untreated animals, urinary deoxypyridinoline (dPyr), as well as C- and N-telopeptides of type I collagen, were significantly elevated 4 weeks after receiving GnRHa, Serum osteocalcin increased in GnRHa-treated animals as early as week 4 and the level was significantly higher than in untreated control animals from weeks 8-24, Estradiol treatment returned all measures of bone turnover to control levels within 2 weeks. The use of biochemical markers as surrogates of bone turnover and loss was validated by measurement of bone mineral density (BMD), which showed a significant reduction at 6 months in estrogen-deficient animals, However, lumbar BMD in animals that received GnRHa and estradiol was similar to that in animals that had not received GnRHa, In conclusion, a monthly depot injection of GnRHa resulted in increased bone turnover due to estrogen deficiency, as early as 4 weeks after treatment. Estrogen administration returned bone turnover to control levels in 2 weeks, This method represents a valid model for evaluating antiresorptive agents in the short term in a nonhuman primate, Furthermore, the data suggest that changes in biochemical markers in response to antiresorptive therapy in humans may be detectable at much earlier time-points than commonly used. (C) 2001 by Elsevier Science Inc. All rights reserved.
引用
收藏
页码:532 / 537
页数:6
相关论文
共 23 条
[1]
Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density [J].
Chesnut, CH ;
Bell, NH ;
Clark, GS ;
Drinkwater, BL ;
English, SC ;
Johnston, CC ;
Notelovitz, M ;
Rosen, C ;
Cain, DF ;
Flessland, KA ;
Mallinak, NJS .
AMERICAN JOURNAL OF MEDICINE, 1997, 102 (01) :29-37
[2]
Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion [J].
Del Campo, MT ;
González-Casaus, ML ;
Aguado, P ;
Bernad, M ;
Carrera, F ;
Martínez, ME .
OSTEOPOROSIS INTERNATIONAL, 1999, 9 (05) :449-454
[3]
DLUGI AM, 1990, FERTIL STERIL, V54, P419
[4]
Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34) - A randomized controlled trial [J].
Finkelstein, JS ;
Klibanski, A ;
Arnold, AL ;
Toth, TL ;
Hornstein, MD ;
Neer, RM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (12) :1067-1073
[5]
Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis [J].
Finkelstein, JS ;
Arnold, AL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (04) :1214-1219
[6]
Fraser WD, 1998, J CLIN LIGAND ASSAY, V21, P102
[7]
Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists [J].
Gnoth, C ;
Gödtke, K ;
Freundl, G ;
Godehardt, E ;
Kienle, E .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1999, 47 (01) :37-41
[9]
17-BETA-ESTRADIOL PROTECTS RATS FROM OSTEOPENIA ASSOCIATED WITH ADMINISTRATION OF THE LUTEINIZING-HORMONE-RELEASING HORMONE (LHRH) AGONIST, BUSERELIN [J].
GOULDING, A ;
FISHER, L .
BONE AND MINERAL, 1991, 13 (01) :47-53
[10]
Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis) [J].
Jerome, CP ;
Turner, CH ;
Lees, CJ .
CALCIFIED TISSUE INTERNATIONAL, 1997, 60 (03) :265-270